Table 2.
Grade ≥ 3 adverse events and dose discontinuation rate in overall and subgroup analysis.
| No. of studies | No. of patients | Arm | Patients | Adverse events (%) | Pooled OR (95% CI) | p-value | I2 (%) | ||
|---|---|---|---|---|---|---|---|---|---|
| Neutropenia2–6,10 | Overall | 5 | 1,541 |
nab, nab + bev sb, sb + bev |
767 774 |
356 (46.4) 362 (46.8) |
0.46 (0.12–1.79) | 0.26 | 96 |
| Subgroup | 4 | 1,006 |
nab sb |
504 502 |
222(44.0) 312(62.2) |
0.26 (0.09–0.78) | 0.02† | 90 | |
| Leukopenia2,3,6,10 | Overall | 4 | 1,393 |
nab, nab + bev sb, sb + bev |
693 700 |
143 (20.6) 153 (21.9) |
0.77 (0.25–2.44) | 0.66 | 92 |
| Subgroup | 3 | 858 |
nab sb |
430 428 |
97(22.6) 132(30.8) |
0.51 (0.16–1.59) | 0.24 | 87 | |
| Sensory neuropathy2–6,10 | Overall | 5 | 1,541 |
nab, nab + bev sb, sb + bev |
767 774 |
139 (18.1) 73 (9.4) |
2.44 (1.42–4.20) | 0.001† | 53 |
| Subgroup | 4 | 1,006 |
nab sb |
504 502 |
69(13.7) 25(5.0) |
2.90 (1.45–5.79) | 0.003† | 48 | |
| Fatigue2,4–6,10 | Overall | 4 | 1,331 |
nab, nab + bev sb, sb + bev |
663 668 |
61 (9.2) 44 (6.6) |
1.34 (0.35–5.22) | 0.67 | 79 |
| Subgroup | 3 | 796 |
nab sb |
400 396 |
18(4.5) 17(4.3) |
1.25 (0.10–5.16) | 0.86 | 85 | |
|
Dose discontinuation |
Overall | 4 | 1,093 |
nab, nab + bev sb, sb + bev |
541 552 |
112 (20.7) 85 (15.4) |
1.23 (0.68–2.25) | 0.49 | 62 |
| Subgroup | 3 | 558 |
nab sb |
278 280 |
42(15.1) 54(19.3) |
0.89 (0.55–1.43) | 0.64 | 0 |
Abbreviations: nab, nanoparticle albumin-bound paclitaxel; sb, solvent-based taxanes; bev, bevacizumab; OR, odds ratio; CI, confidence interval.
†Statistically significant when p < 0.05.
Overall includes all studies with adverse events data.
Subgroup includes therapy with nab-paclitaxel vs solvent-based taxanes (sb-paclitaxel and docetaxel).